October 3rd 2024
After 30+ years of clinical experience with clozapine, it is time for professional psychiatry to demand an end to this discriminatory clozapine REMS program.
September 19th 2024
Meeting the needs of the dying and their families requires a deep and clear understanding of competent and compassionate care.
September 18th 2024
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Poll: Do You Feel Prepared to Prescribe the Newly Approved First-In-Class Muscarinic Agonist?
September 27th 2024The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?
Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics
September 25th 2024Experts in the management of mood disorders comment on the evolving management of major depressive disorder, emphasizing findings from the STAR*D trial, updated treatment guidelines, and the role of precision medicine and the shift toward personalized, rapid-acting treatments to improve patient outcomes.
New Data Shows How Best to Switch Patients With Schizophrenia to Risperidone
New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.